|
- Dyne Therapeutics - A biotechnology company developing nucleic acid . . .
Culture and careers Our commitment to people living with neuromuscular diseases is our greatest strength Hear our Dynamos share their perspective on what makes Dyne a special place to work Learn more
- Dyne readies FDA push after DMD exon 51 med excels in trial
Dyne’s phase 1 2 Deliver study enrolled 86 patients with DMD amenable to 51 skipping, who make up about 13% of the overall DMD patient population, according to a Dec 8 company presentation
- Dyne - Wikipedia
The dyne (symbol: dyn; from Ancient Greek δύναμις (dúnamis) 'power, force') is a derived unit of force specified in the centimetre–gram–second (CGS) system of units, a predecessor of the modern SI
- Dyne plans to submit next-gen Duchenne drug to FDA - STAT
Dyne Therapeutics plans to submit its next-gen Duchenne muscular dystrophy drug to the FDA after a successful trial
- Dyne Therapeutics Announces Positive Topline Results from . . . - BioSpace
Dyne also continues to pursue approval pathways outside of the U S for z-rostudirsen in patients with DMD who are amenable to exon 51 skipping Investor Webcast Dyne will host a conference call and webcast to discuss these updates today, December 8, 2025, at 8:00 a m ET and a replay will be accessible for 90 days following the presentation
- Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares . . .
Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares soar Dyne is readying a competitor to Sarepta’s Exondys 51 Elsewhere, two obesity drugs showed promise and a protein-degrading medicine displayed “biologic-like or better efficacy,” one analyst said
- Dyne Therapeutics Aims to Raise $300M in Public Offering, Prepares to . . .
NEW YORK – Dyne Therapeutics on Monday said it has started an underwritten public offering in which it intends to sell at least $300 million shares of its common stock As part of the offering of $300 million worth of shares, Waltham, Massachusetts-based Dyne also will grant the underwriters a 30
- Dyne Therapeutics (DYN) FDA Approvals - MarketBeat
DYNE-251 is a drug developed by Dyne Therapeutics for the following indication: Duchenne Muscular Dystrophy This drug is under review by the U S Food and Drug Administration (FDA)
|
|
|